Growth factor antagonists for the treatment of diabetic vascular complications

Ronald Tilton, R. A F Dixon, T. A. Brock

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Diabetic vascular disease is characterised by altered vascular reactivity and blood flow, hyperpermeability, hyperproliferative responses, and increased extracellular matrix deposition in tissues that are sites of complications. These vascular functional and structural changes have been linked to excessive glucose metabolism in target organs via at least three pathophysiological mechanisms, including increased sorbitol (polyol) pathway activity, increased non-enzymatic glycation of vascular wall proteins, and increased protein kinase C (PKC) activity. These potential mechanisms of glucose toxicity remain the subject of intense scientific investigation, and therapies targeting each of them are being evaluated in clinical trials. It is becoming increasingly clear that excessive production of growth factors provides a common denominator linking these diverse mechanisms of glucose toxicity to the functional and structural vascular alterations associated with diabetes. Increased expression of vascular endothelial growth factor (VEGF) has been linked to increased metabolism of glucose via the sorbitol pathway, to non-enzymatic glycation, and to increased PKC activity, and appears to modulate the hyperpermeability and hyperproliferative responses of diabetes. Consequently, because of the unmet medical need and market size, numerous pharmaceutical and biotechnology companies have initiated research programmes evaluating growth factor antagonists as a potential therapeutic approach for treating complications associated with diabetic vascular disease. However, before growth factor antagonists can enter clinical testing, a number of important issues must be clarified, including the physiological effect of chronic growth factor inhibition, which appears to be necessary for ameliorating chronic vascular deterioration of diabetes, and administration routes, especially for protein-based therapies.

Original languageEnglish (US)
Pages (from-to)1671-1684
Number of pages14
JournalExpert Opinion on Investigational Drugs
Volume6
Issue number11
DOIs
StatePublished - 1997
Externally publishedYes

Fingerprint

Diabetic Angiopathies
Blood Vessels
Intercellular Signaling Peptides and Proteins
Glucose
Sorbitol
Protein Kinase C
Biotechnology
Vascular Endothelial Growth Factor A
Extracellular Matrix
Proteins
Therapeutics
Clinical Trials
Research
Pharmaceutical Preparations

Keywords

  • Angiogenesis
  • Diabetic vascular complications
  • Fibroblast growth factor
  • Growth factor antagonist
  • Insulin-like growth factor
  • Platelet-derived growth factor
  • Retinopathy
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Pharmacology

Cite this

Growth factor antagonists for the treatment of diabetic vascular complications. / Tilton, Ronald; Dixon, R. A F; Brock, T. A.

In: Expert Opinion on Investigational Drugs, Vol. 6, No. 11, 1997, p. 1671-1684.

Research output: Contribution to journalArticle

Tilton, Ronald ; Dixon, R. A F ; Brock, T. A. / Growth factor antagonists for the treatment of diabetic vascular complications. In: Expert Opinion on Investigational Drugs. 1997 ; Vol. 6, No. 11. pp. 1671-1684.
@article{8b3d4e8069c240e59d45246f79b17241,
title = "Growth factor antagonists for the treatment of diabetic vascular complications",
abstract = "Diabetic vascular disease is characterised by altered vascular reactivity and blood flow, hyperpermeability, hyperproliferative responses, and increased extracellular matrix deposition in tissues that are sites of complications. These vascular functional and structural changes have been linked to excessive glucose metabolism in target organs via at least three pathophysiological mechanisms, including increased sorbitol (polyol) pathway activity, increased non-enzymatic glycation of vascular wall proteins, and increased protein kinase C (PKC) activity. These potential mechanisms of glucose toxicity remain the subject of intense scientific investigation, and therapies targeting each of them are being evaluated in clinical trials. It is becoming increasingly clear that excessive production of growth factors provides a common denominator linking these diverse mechanisms of glucose toxicity to the functional and structural vascular alterations associated with diabetes. Increased expression of vascular endothelial growth factor (VEGF) has been linked to increased metabolism of glucose via the sorbitol pathway, to non-enzymatic glycation, and to increased PKC activity, and appears to modulate the hyperpermeability and hyperproliferative responses of diabetes. Consequently, because of the unmet medical need and market size, numerous pharmaceutical and biotechnology companies have initiated research programmes evaluating growth factor antagonists as a potential therapeutic approach for treating complications associated with diabetic vascular disease. However, before growth factor antagonists can enter clinical testing, a number of important issues must be clarified, including the physiological effect of chronic growth factor inhibition, which appears to be necessary for ameliorating chronic vascular deterioration of diabetes, and administration routes, especially for protein-based therapies.",
keywords = "Angiogenesis, Diabetic vascular complications, Fibroblast growth factor, Growth factor antagonist, Insulin-like growth factor, Platelet-derived growth factor, Retinopathy, Vascular endothelial growth factor",
author = "Ronald Tilton and Dixon, {R. A F} and Brock, {T. A.}",
year = "1997",
doi = "10.1517/13543784.6.11.1671",
language = "English (US)",
volume = "6",
pages = "1671--1684",
journal = "Expert Opinion on Investigational Drugs",
issn = "1354-3784",
publisher = "Taylor and Francis Ltd.",
number = "11",

}

TY - JOUR

T1 - Growth factor antagonists for the treatment of diabetic vascular complications

AU - Tilton, Ronald

AU - Dixon, R. A F

AU - Brock, T. A.

PY - 1997

Y1 - 1997

N2 - Diabetic vascular disease is characterised by altered vascular reactivity and blood flow, hyperpermeability, hyperproliferative responses, and increased extracellular matrix deposition in tissues that are sites of complications. These vascular functional and structural changes have been linked to excessive glucose metabolism in target organs via at least three pathophysiological mechanisms, including increased sorbitol (polyol) pathway activity, increased non-enzymatic glycation of vascular wall proteins, and increased protein kinase C (PKC) activity. These potential mechanisms of glucose toxicity remain the subject of intense scientific investigation, and therapies targeting each of them are being evaluated in clinical trials. It is becoming increasingly clear that excessive production of growth factors provides a common denominator linking these diverse mechanisms of glucose toxicity to the functional and structural vascular alterations associated with diabetes. Increased expression of vascular endothelial growth factor (VEGF) has been linked to increased metabolism of glucose via the sorbitol pathway, to non-enzymatic glycation, and to increased PKC activity, and appears to modulate the hyperpermeability and hyperproliferative responses of diabetes. Consequently, because of the unmet medical need and market size, numerous pharmaceutical and biotechnology companies have initiated research programmes evaluating growth factor antagonists as a potential therapeutic approach for treating complications associated with diabetic vascular disease. However, before growth factor antagonists can enter clinical testing, a number of important issues must be clarified, including the physiological effect of chronic growth factor inhibition, which appears to be necessary for ameliorating chronic vascular deterioration of diabetes, and administration routes, especially for protein-based therapies.

AB - Diabetic vascular disease is characterised by altered vascular reactivity and blood flow, hyperpermeability, hyperproliferative responses, and increased extracellular matrix deposition in tissues that are sites of complications. These vascular functional and structural changes have been linked to excessive glucose metabolism in target organs via at least three pathophysiological mechanisms, including increased sorbitol (polyol) pathway activity, increased non-enzymatic glycation of vascular wall proteins, and increased protein kinase C (PKC) activity. These potential mechanisms of glucose toxicity remain the subject of intense scientific investigation, and therapies targeting each of them are being evaluated in clinical trials. It is becoming increasingly clear that excessive production of growth factors provides a common denominator linking these diverse mechanisms of glucose toxicity to the functional and structural vascular alterations associated with diabetes. Increased expression of vascular endothelial growth factor (VEGF) has been linked to increased metabolism of glucose via the sorbitol pathway, to non-enzymatic glycation, and to increased PKC activity, and appears to modulate the hyperpermeability and hyperproliferative responses of diabetes. Consequently, because of the unmet medical need and market size, numerous pharmaceutical and biotechnology companies have initiated research programmes evaluating growth factor antagonists as a potential therapeutic approach for treating complications associated with diabetic vascular disease. However, before growth factor antagonists can enter clinical testing, a number of important issues must be clarified, including the physiological effect of chronic growth factor inhibition, which appears to be necessary for ameliorating chronic vascular deterioration of diabetes, and administration routes, especially for protein-based therapies.

KW - Angiogenesis

KW - Diabetic vascular complications

KW - Fibroblast growth factor

KW - Growth factor antagonist

KW - Insulin-like growth factor

KW - Platelet-derived growth factor

KW - Retinopathy

KW - Vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=0030725818&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030725818&partnerID=8YFLogxK

U2 - 10.1517/13543784.6.11.1671

DO - 10.1517/13543784.6.11.1671

M3 - Article

C2 - 15989571

AN - SCOPUS:0030725818

VL - 6

SP - 1671

EP - 1684

JO - Expert Opinion on Investigational Drugs

JF - Expert Opinion on Investigational Drugs

SN - 1354-3784

IS - 11

ER -